Effects of long-term treatment with Dienogest on the quality of life and sexual function of women affected by endometriosis-associated pelvic pain
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Purpose: The aim of this prospective study was to evaluate quality of life (QoL) and sexual function of women affected by endometriosis pain treated with Dienogest (DNG) for 24 months. Patients and methods: Fifty-four women constituted the study group and were given DNG 2 mg/daily; 38 women were given non-steroidal anti-inflammatory drugs (NSAIDs) and constituted the control group. To define endometriosis-associated pelvic pain, dysmenorrhea and dyspareunia the Visual Analogic Scale (VAS) was used. The Short Form-36 (SF-36), the Female Sexual Function Index (FSFI) and the Female Sexual Distress Scale (FSDS) were used to assess the QoL, sexual function and the sexual distress, respectively. The study included five follow-ups at 3, 6, 12, 18 and 24 months. Results: Slight improvements in chronic pelvic pain, dysmenorrhea and dyspareunia were observed in the study group at 3 months ( p <0.05) and improved more from 6 to 24 months of DNG treatment ( p <0.001). QoL improved with a similar trend: at 3 months the improvement was significant in several categories ( p <0.05), and from 6 to 24 months in all categories ( p <0.001). The FSFI score did not change at the 3 month follow-up ( p =not significant [NS]) but it improved from 6 to 24 months ( p <0.001). A similar trend was observed for the FSDS score ( p <0.001). No change was observed in the control group ( p =NS). Conclusion: Long-term treatment with DNG 2 mg once-daily in women with endometriosis-associated pelvic pain may have positive effects on the QoL and sexual life, confirming the observations of the previous study on the first 6 months of treatment. Keywords: dyspareunia, endometriosis, chronic pelvic pain, long term dienogest, quality of life, sexual life
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Patients treated with DNG have also shown an improvement of sexual functioning [194] and QoL [187, 199].”
From Hormonal treatments for endometriosis: The endocrine background (2022) · cites this paper as [199]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ESHRE guideline: management of women with endometriosis
Dunselman, G. A. J., Vermeulen, N., Becker, C., Calhaz-Jorge, C., D'Hooghe, T., De Bie, B., Heikinheimo, O., Horne, A. W., Kiesel, L., Nap, A., et al. (2014) · Human Reproduction · doi:10.1093/humrep/det457 · Cited by 2,211 · cited 1×
“The current study has some limitations: endometriosis was not confirmed by laparoscopic exploration and biopsy also because the goal was to investigate about medical therapy and it’s not encouraged by the guidelines to perform laparoscopy without treating the lesions during the same surgery.(2) The lack of randomizati…”
BackgroundEndometriosis: pathogenesis and treatment
Vercellini, P., Viganò, P., Somigliana, E., & Fedele, L. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.255 · Cited by 1,940
ESHRE guideline for the diagnosis and treatment of endometriosis
Kennedy, S., Bergqvist, A., Chapron, C., D’Hooghe, T., Dunselman, G., Greb, R., Hummelshoj, L., Prentice, A., & Saridogan, E. (2005) · Human Reproduction · doi:10.1093/humrep/dei135 · Cited by 1,584 · cited 1×
“31,32 The multidisciplinary nature of chronic pelvic pain may cause confusion for a correct diagnosis and treat-ment.”
Gallagher, E. J., Liebman, M., & Bijur, P. E. (2001) · Annals of Emergency Medicine · doi:10.1067/mem.2001.118863 · Cited by 1,024
Derogatis, L. R., Rosen, R., Leiblum, S., Burnett, A., & Heiman, J. (2002) · Journal of Sex & Marital Therapy · doi:10.1080/00926230290001448 · Cited by 791
The Factor Structure of the SF-36 Health Survey in 10 Countries
Ware, J. E., Kosinski, M., Gandek, B., Aaronson, N. K., Apolone, G., Bech, P., Brazier, J., Bullinger, M., Kaasa, S., Leplège, A., et al. (1998) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(98)00107-3 · Cited by 655
Nonsteroidal anti-inflammatory drugs for dysmenorrhoea
Marjoribanks, J., Ayeleke, R. O., Farquhar, C., & Proctor, M. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001751.pub3 · Cited by 562 · cited 1×
“Several women take on-demand non-steroidal anti-inflammatory drugs (NSAIDs) as first line agents to control their pelvic pain.(14) Hormonal treatment is adopted only after a specialist diagnoses endometriosis as the cause of the pelvic pain.”
BackgroundAnxiety and depression in patients with endometriosis: impact and management challenges
Laganà, A. S., La Rosa, V. L., Rapisarda, A. M. C., Valenti, G., Sapia, F., Chiofalo, B., Rossetti, D., Ban Frangež, H., Vrtačnik Bokal, E., & Giovanni Vitale, S. (2017) · International Journal of Women's Health · doi:10.2147/ijwh.s119729 · Cited by 405
Self-citationTreatment of pelvic pain associated with endometriosis: a committee opinion
(2014) · Fertility and Sterility · doi:10.1016/j.fertnstert.2014.02.012 · Cited by 397 · cited 1×
“33 The delay of an appropriate treatment negatively affects the QoL of woman, often not restricting the progression of endometriosis.”
Priorities for Endometriosis Research: Recommendations From an International Consensus Workshop
Rogers, P. A. W., D’Hooghe, T. M., Fazleabas, A., Gargett, C. E., Giudice, L. C., Montgomery, G. W., Rombauts, L., Salamonsen, L. A., & Zondervan, K. T. (2009) · Reproductive Sciences · doi:10.1177/1933719108330568 · Cited by 346 · cited 1×
“Introduction Endometriosis-associated pelvic pain affects approximately 10% of women of reproductive age.(1)”
Casper, R. F. (2017) · Fertility and Sterility · doi:10.1016/j.fertnstert.2017.01.003 · Cited by 205
Sasagawa, S., Shimizu, Y., Kami, H., Takeuchi, T., Mita, S., Imada, K., Kato, S., & Mizuguchi, K. (2008) · Steroids · doi:10.1016/j.steroids.2007.10.003 · Cited by 177
The use of newer progestins for contraception
Sitruk-Ware, R., & Nath, A. (2010) · Contraception · doi:10.1016/j.contraception.2010.04.004 · Cited by 174 · cited 1×
“26 Moreover, circulating estradiol levels during treatment with DNG 2 mg daily are similar to those in the early follicular phase of the menstrual cycle.”
Medical Management of Endometriosis
RAFIQUE, S., & DECHERNEY, A. H. (2017) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000292 · Cited by 173 · cited 1×
“The moderate suppression of estradiol with DNG may represent a potential advantage over other therapies, such as GnRH agonists, which require estrogen add-back if used for more than 6 months.(28)”
Márki, G., Bokor, A., Rigó, J. J., & Rigó, A. (2017) · Human Reproduction · doi:10.1093/humrep/dex091 · Cited by 165 · cited 1×
“34 DNG represents a promising medication for the long-term management of endometriosis.”
Current and emerging treatment options for endometriosis
Ferrero, S., Evangelisti, G., & Barra, F. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1494154 · Cited by 152
Nappi, R. E., Albani, F. L. M., Vaccaro, P., Gardella, B., Salonia, A., Chiovato, L., Spinillo, A., & Polatti, F. (2008) · Gynecological Endocrinology · doi:10.1080/09513590801925596 · Cited by 148 · cited 1×
“Sexual behavior was assessed using the self-administered Female Sexual Function Index (FSFI) validated in the Italian gynecological population.(21) An FSFI cut-off of ≤26.”
MethodMuzii, L., Di Tucci, C., Achilli, C., Di Donato, V., Musella, A., Palaia, I., & Panici, P. B. (2016) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2015.08.074 · Cited by 142 · cited 1×
“Moreover, women affected by chronic pelvic pain should use drugs having a continuous regimen, including hormonal contraceptives.(13) Several women take on-demand non-steroidal anti-inflammatory drugs (NSAIDs) as first line agents to control their pelvic pain.”
BackgroundWalch, K., Unfried, G., Huber, J., Kurz, C., van Trotsenburg, M., Pernicka, E., & Wenzl, R. (2009) · Contraception · doi:10.1016/j.contraception.2008.07.017 · Cited by 128
Bedaiwy, M. A., Allaire, C., & Alfaraj, S. (2017) · Fertility and Sterility · doi:10.1016/j.fertnstert.2016.12.024 · Cited by 126
Nieri, P., Martinotti, E., Testai, L., Adinolfi, B., Calderone, V., & Breschi, M. C. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)02831-5 · Cited by 126
Okada, H. (2001) · Molecular Human Reproduction · doi:10.1093/molehr/7.4.341 · Cited by 104 · cited 1×
“16,17 We previously investigated endometriosis-associated pelvic pain of women on DNG for 6 months and observed an improvement in pain, QoL and sexual function.”
Vercellini, P., Frattaruolo, M. P., Somigliana, E., Jones, G. L., Consonni, D., Alberico, D., & Fedele, L. (2013) · Human Reproduction · doi:10.1093/humrep/det041 · Cited by 97 · cited 1×
“31,32 The multidisciplinary nature of chronic pelvic pain may cause confusion for a correct diagnosis and treat-ment.”
Dienogest: A New Therapeutic Agent for the Treatment of Endometriosis
Harada, T., & Taniguchi, F. (2010) · Women's Health · doi:10.2217/whe.09.72 · Cited by 92 · cited 1×
“Dienogest (DNG) is a synthetic progestin that is currently used for clinical treatment of endometriosis with a dose of 2 mg daily.(15) The steroid also has direct antiproliferative, immunologic and antiangiogenic activities that contribute to the reduction of endometriosis-associated symptoms and exhibits highly selec…”
MethodCaruso, S., Iraci, M., Cianci, S., Fava, V., Casella, E., & Cianci, A. (2016) · Journal of Endocrinological Investigation · doi:10.1007/s40618-016-0460-6 · Cited by 92
Self-citationCaruso, S., Iraci, M., Cianci, S., Casella, E., Fava, V., & Cianci, A. (2015) · Journal of Endocrinological Investigation · doi:10.1007/s40618-015-0383-7 · Cited by 90 · cited 1×
“18 The study aims to evaluate how many women rested on DNG at 24-month follow-up, and to measure the pain level (primary endpoint), sexual function and QoL (secondary endpoints).”
Self-citationFoster, R. H., & Wilde, M. I. (1998) · Drugs · doi:10.2165/00003495-199856050-00007 · Cited by 87
Aromatase and endometriosis: estrogens play a role
Ferrero, S., Remorgida, V., Maganza, C., Venturini, P. L., Salvatore, S., Papaleo, E., Candiani, M., & Leone Roberti Maggiore, U. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12411 · Cited by 85
Morotti, M., Sozzi, F., Remorgida, V., Venturini, P. L., & Ferrero, S. (2014) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2014.10.036 · Cited by 84 · cited 1×
“24 We observed a concomitant and gradual improvement of sexual function and a reduction of sexual distress starting from the 6th month follow-up until the 24-month follow-up.”
Klipping, C., Duijkers, I., Remmers, A., Faustmann, T., Zurth, C., Klein, S., & Schuett, B. (2012) · The Journal of Clinical Pharmacology · doi:10.1177/0091270011423664 · Cited by 83 · cited 1×
“It is interesting to note that DNG 2 mg daily provides ovulation inhibition, but ovarian activity is not completely suppressed; 25 thus it has not been approved as a contraceptive.”
Carty, C. L., Spencer, K. L., Setiawan, V. W., Fernandez-Rhodes, L., Malinowski, J., Buyske, S., Young, A., Jorgensen, N. W., Cheng, I., Carlson, C. S., et al. (2013) · Human Reproduction · doi:10.1093/humrep/det071 · Cited by 74
Caruso, S., Cianci, S., Vitale, S. G., Fava, V., Cutello, S., & Cianci, A. (2018) · The European Journal of Contraception & Reproductive Health Care · doi:10.1080/13625187.2018.1433824 · Cited by 72
Self-citationDienogest, a synthetic steroid, suppresses both embryonic and tumor-cell-induced angiogenesis
Nakamura, M., Katsuki, Y., Shibutani, Y., & Oikawa, T. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(99)00765-7 · Cited by 63 · cited 1×
“16,17 We previously investigated endometriosis-associated pelvic pain of women on DNG for 6 months and observed an improvement in pain, QoL and sexual function.”
Grandi, G., Xholli, A., Napolitano, A., Palma, F., & Cagnacci, A. (2015) · Reproductive Sciences · doi:10.1177/1933719114556488 · Cited by 46 · cited 1×
“30 Our study performed a clinical diagnosis of endome-triosis-associated pelvic pain, but it is necessary to point out that the gold standard investigation to a de fi nitive diagnosis of most forms of endometriosis is laparoscopy for women presenting symptoms suggestive of endometriosis.”
Yucel, N., Baskent, E., Karamustafaoglu Balci, B., & Goynumer, G. (2018) · Australian and New Zealand Journal of Obstetrics and Gynaecology · doi:10.1111/ajo.12773 · Cited by 30
Management of Chronic Pelvic Pain
Bishop, L. A. (2017) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000299 · Cited by 23 · cited 1×
“Progestins or hormonal contraceptives,(3,5) GnRH agonists,(6,7) aromatase inhibitors,(8) etonogestrel subdermal implant,(9) or levonorgestrel-releasing intrauterine devices(10,11) are used to counteract the ovarian estrogenic secretion on the endometrium-like tissue developing outside the uterus.(12) Even if each of t…”
BackgroundYeh, J., Kim, B. S., Peresie, J., & Page, C. (2009) · Reproductive Sciences · doi:10.1177/1933719109339217 · Cited by 11
Cited by
Della Corte, L., Di Filippo, C., Gabrielli, O., Reppuccia, S., La Rosa, V. L., Ragusa, R., Fichera, M., Commodari, E., Bifulco, G., & Giampaolino, P. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17134683 · Cited by 387
“Even medical therapy, in particular progestin, can improve the symptoms of patients [20].”
BackgroundHormonal treatments for endometriosis: The endocrine background
Vannuccini, S., Clemenza, S., Rossi, M., & Petraglia, F. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09666-w · Cited by 336
Use of dienogest in endometriosis: a narrative literature review and expert commentary
Murji, A., Biberoğlu, K., Leng, J., Mueller, M. D., Römer, T., Vignali, M., & Yarmolinskaya, M. (2020) · Current Medical Research and Opinion · doi:10.1080/03007995.2020.1744120 · Cited by 116
Gender Differences and Quality of Life in Parkinson’s Disease
Crispino, P., Gino, M., Barbagelata, E., Ciarambino, T., Politi, C., Ambrosino, I., Ragusa, R., Marranzano, M., Biondi, A., & Vacante, M. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18010198 · Cited by 100
Quality of Life in Women with Deep Endometriosis: A Cross-Sectional Study
Yela, D. A., Quagliato, I. D. P., & Benetti-Pinto, C. L. (2020) · Revista Brasileira de Ginecologia e Obstetrícia / RBGO Gynecology and Obstetrics · doi:10.1055/s-0040-1708091 · Cited by 54
Metadata
- Authors
- Caruso, S., Iraci, M., Cianci, S., Vitale, S. G., Fava, V., & Cianci, A.
- Affiliations
- University of Catania (IT)
- Corresponding author
- Vitale, Salvatore Giovanni
- ORCID
- Venue
- Journal of Pain Research
- Publisher
- Informa UK Limited
- Published
- 2019-07
- Volume
- Volume 12
- Pages
- 2371-2378
- ISSN
- 1178-7090 (ISSN-L)
- PMC
- PMC6681157
- OpenAlex
- W2965687471
- Cited by
- 73
- References
- 37
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 10 · 2023: 10 · 2022: 9 · 2021: 18 · 2020: 14 · 2019: 1
- FWCI
- 10.04
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Pain Research (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- UNICA IRIS Institutional Research Information System (University of Cagliari) (submittedVersion, other-oa)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- Funders
- Università di Catania
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Menstrual Health and Disorders
- Health Sciences › Medicine › Obstetrics and Gynecology › Ectopic Pregnancy Diagnosis and Management
- Keywords
- dienogest, endometriosis, chronic pelvic pain, dysmenorrhea, dyspareunia, quality of life, sexual function, sexual distress, long-term treatment, nonsteroidal anti-inflammatory drugs, progestogens
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.